moxifloxacin has been researched along with Eye Infections, Viral in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T; Hu, Y; Li, L; Liu, H; Liu, M; Wang, F; Wang, Y; Xia, H; Zhang, L; Zhao, S | 1 |
| Ozturker, ZK | 1 |
| Mishra, B; Nayak, B; Panigrahi, MK; Poddar, C; Tripathy, S | 1 |
| Chen, A; Jabbour, S; Shekhawat, NS; Woreta, FA | 1 |
1 review(s) available for moxifloxacin and Eye Infections, Viral
| Article | Year |
|---|---|
Conjunctivitis as sole symptom of COVID-19: A case report and review of literature.
Topics: Administration, Ophthalmic; Adult; Anti-Bacterial Agents; Conjunctivitis, Viral; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Eye Infections, Viral; Humans; Male; Moxifloxacin; Nurses; Occupational Exposure; Ophthalmic Solutions; Pneumonia, Viral; RNA, Viral; SARS-CoV-2; Tears; Tomography, X-Ray Computed | 2021 |
3 other study(ies) available for moxifloxacin and Eye Infections, Viral
| Article | Year |
|---|---|
Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid in tear and conjunctival secretions of a non-conjunctivitis COVID-19 patient with obstruction of common lacrimal duct.
Topics: Aged; Anti-Bacterial Agents; Conjunctiva; Conjunctivitis, Viral; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Eye Infections, Viral; Flow Cytometry; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 6, Human; High-Throughput Nucleotide Sequencing; HIV Protease Inhibitors; Humans; Lacrimal Duct Obstruction; Lopinavir; Male; Medicine, Chinese Traditional; Moxifloxacin; Nasopharynx; Nucleic Acids; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Roseolovirus Infections; SARS-CoV-2; Tears | 2020 |
Late manifestation of follicular conjunctivitis in ventilated patient following COVID-19 positive severe pneumonia.
Topics: Aged; Anti-Bacterial Agents; Betacoronavirus; Conjunctivitis, Viral; Coronavirus Infections; COVID-19; Eye Infections, Viral; Follow-Up Studies; Humans; Lubricants; Male; Moxifloxacin; Ophthalmic Solutions; Pandemics; Pneumonia, Viral; Respiration, Artificial; SARS-CoV-2 | 2020 |
Presumed Herpes Zoster Ophthalmicus Reactivation Following Recombinant Zoster Vaccination.
Topics: Aged; Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Combination; Erythromycin; Eye Infections, Viral; Female; Herpes Zoster Ophthalmicus; Herpes Zoster Vaccine; Herpesvirus 3, Human; Humans; Immunization, Secondary; Latent Infection; Moxifloxacin; Vaccination; Valacyclovir; Virus Activation; Visual Acuity | 2021 |